After studying chemistry at the University of Missouri and post-graduate studies in medicinal chemistry at the University of Kansas, Steve enjoyed a brief stint with Farmland Industries researching agrochemicals in his hometown of Kansas City, Missouri. Upon the closure of Farmland’s R&D facility, Steve moved east and resumed his career in pharmaceutical research as a medicinal chemist with SmithKline Beecham in the Philadelphia area. His work at SB was focused primarily on peptidomimetic inhibitors of the newly-characterized HIV protease as potential treatments for AIDS. Steve then returned to the Midwest as a medicinal chemist with Abbott Laboratories where he was instrumental in helping discover several preclinical candidates for oncology and cardiovascular diseases in the renin inhibitor, squalene synthase, and farnesyl transferase programs.
Moving from the Chicagoland area to Ann Arbor, Michigan, Steve accepted a position as a medicinal chemist with Pfizer in 2001. His research at Pfizer resulted in a number of clinical candidates for multiple kinase and nuclear hormone receptor targets, highlighted by the co-discovery of dacomitinib, currently approved and marketed as Vizimpro® for metastatic non-small cell lung carcinoma. Upon the closure of the Pfizer Ann Arbor site, Steve joined Life Technologies in Madison, Wisconsin, developing novel, fluorescently-linked, small molecule probes of various kinases and epigenetic targets to use in new TR-FRET and FP high-throughput screening assays.
In addition, he wrote and revised manufacturing protocols for a variety of products to streamline their manufacture and comply with the requirements of LT’s quality management system. In 2012, Steve joined AMRI, initially in the synthetic chemistry group and ultimately as the leader of the staff running the Automated Synthesis Lab. In April of 2019, Steve transitioned to Cogent Scientific where he is currently the team lead for Cogent’s synthetic group, which includes the Automated Synthesis Lab, the Hydrogenation & Pressure Lab, and the Catalysis Lab.
Steve graduated from the University of Missouri with a B.S. in Chemistry. Steve continued his education at the University of Kansas with two years of graduate study in their Medicinal/Organic Chemistry PhD program.